Pharmacotherapy for squamous-cell carcinoma of the head and neck

被引：11

作者：

Papaspyrou, Giorgos ^{[2
]}

Werner, Jochen A. ^{[2
]}

Dietz, Andreas ^{[1
]}

机构：

[1] Dept Otolaryngol Head & Neck Surg, D-04103 Leipzig, Germany

[2] Univ Marburg, Dept Otolaryngol Head & Neck Surg, D-35037 Marburg, Germany

来源：

EXPERT OPINION ON PHARMACOTHERAPY | 2011年 / 12卷 / 03期

关键词：

GROWTH-FACTOR RECEPTOR; PHASE-II TRIAL; TYROSINE KINASE INHIBITOR; RECURRENT HEAD; METASTATIC/RECURRENT HEAD; ANTIBODY CETUXIMAB; PLUS CETUXIMAB; SINGLE-AGENT; CISPLATIN; CANCER;

D O I：

10.1517/14656566.2011.523698

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Areas covered: The purpose of this review is to provide an update on the pharmacotherapy for the treatment of HNSCC focusing mainly on molecular-targeted therapies. An overview of the different novel therapeutic agents that can selectively inhibit signaling pathways and receptors that are involved in the development and progression of cancer especially in HNSCC is presented. Expert opinion: The treatment of HNSCC is traditionally based on surgery and radiotherapy for early-stage HNSCC; however, chemotherapy is no longer used only for palliation, and individualized patient treatment assisted by molecular-targeted therapies represents a future therapeutic challenge.

引用

页码：397 / 409

页数：13

共 72 条

[1] Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines [J].

Aissat, Nasredine ;

Le Tourneau, Christophe ;

Ghoul, Aida ;

Serova, Maria ;

Bieche, Ivan ;

Lokiec, Francois ;

Raymond, Eric ;

Faivre, Sandrine .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 62 (02) :305-313

[2]

[Anonymous], 2008, Cancer Facts Figures 2008

[3]

[Anonymous], CANC J CLIN

[4] Competing causes of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with chemoradiotherapy [J].

Argiris, A ;

Brockstein, BE ;

Haraf, DJ ;

Stenson, KM ;

Mittal, BB ;

Kies, MS ;

Rosen, FR ;

Jovanovic, B ;

Vokes, EE .

CLINICAL CANCER RESEARCH, 2004, 10 (06) :1956-1962

[5] Inostamycin prevents malignant phenotype of cancer: inhibition of phosphatidylinositol synthesis provides a therapeutic advantage for head and neck squamous cell carcinoma [J].

Baba, Yuh ;

Kato, Yasumasa ;

Ogawa, Kaoru .

CELL BIOLOGY INTERNATIONAL, 2010, 34 (02) :171-175

[6] Insulin-like growth factor receptor as a therapeutic target in head and neck cancer [J].

Barnes, Christopher J. ;

Ohshiro, Kazufumi ;

Rayala, Suresh K. ;

El-Naggar, Adel K. ;

Kumar, Rakesh .

CLINICAL CANCER RESEARCH, 2007, 13 (14) :4291-4299

[7] Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck [J].

Baselga, J ;

Trigo, JM ;

Bourhis, J ;

Tortochaux, J ;

Cortés-Funes, H ;

Hitt, R ;

Gascón, P ;

Arnellal, N ;

Harstrick, A ;

Eckardt, A .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (24) :5568-5577

[8]

BASTHOLT L, P ASCO 05

[9]

Belón J, 2005, J CLIN ONCOL, V23, p515S

[10] Defining risk levels in locally advanced head and neck cancers:: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (#9501) [J].

Bernier, J ;

Cooper, JS ;

Pajak, TF ;

van Glabbeke, M ;

Bourhis, J ;

Forastiere, A ;

Ozsahin, EM ;

Jacobs, JR ;

Jassem, J ;

Ang, KK ;

Lefèbvre, JL .

HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2005, 27 (10) :843-850

← 1 2 3 4 5 6 7 8 →